Ronnie Per-Arne Berntsson

Ronnie Per-Arne Berntsson

Auto-generated profile, based on publicly available information

Ronnie Per-Arne Berntsson

Department of Medical Biochemistry and Biophysics Umeå University Umeå Sweden

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2010 in FEBS Letters
Verified
Journal Article
Closed access
RBRonnie P.-A. Berntsson
Ronnie P.-A. Berntsson
SSSander H.J. Smits
Sander H.J. Smits
LSLutz Schmitt
Lutz Schmitt
DSDirk-Jan Slotboom
Dirk-Jan Slotboom
BPBert Poolman
Bert Poolman

2 April 2014 in Nature
Verified
Journal Article
Closed access
HGHelge Gad
Helge Gad
TKTobias Koolmeister
Tobias Koolmeister
AJAnn-Sofie Jemth
Ann-Sofie Jemth
SESaeed Eshtad
Saeed Eshtad
SJSylvain A Jacques
Sylvain A Jacques
THThomas Helleday
Thomas Helleday

16 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJordi Carreras-Puigvert
Jordi Carreras-Puigvert
MZMarinka Zitnik
Marinka Zitnik
AJAnn-Sofie Jemth
Ann-Sofie Jemth
MCMegan Carter
Megan Carter
JUJudith E. Unterlass
Judith E. Unterlass
THThomas Helleday
Thomas Helleday
The NUDIX enzymes are involved in cellular metabolism and homeostasis, as well as mRNA processing. Although highly conserved throughout all organisms, their biological roles and biochemical redundancies remain largely unclear. To address this, we globally resolve their individual properties and inter-relationships. We purify 18 of the human NUDIX proteins and screen 52 substrates, providing a substrate redundancy map. Using crystal structures, we generate sequence alignment analyses revealing four major structural classes. To a certain extent, their substrate preference redundancies correlate with structural classes, thus linking structure and activity relationships. To elucidate interdependence among the NUDIX hydrolases, we pairwise deplete them generating an epistatic interaction map, evaluate cell cycle perturbations upon knockdown in normal and cancer cells, and analyse their protein and mRNA expression in normal and cancer tissues. Using a novel FUSION algorithm, we integrate all data creating a comprehensive NUDIX enzyme profile map, which will prove fundamental to understanding their biological functionality.

26 June 2011 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
GEGuus B Erkens
Guus B Erkens
RBRonnie P-A Berntsson
Ronnie P-A Berntsson
FFFaizah Fulyani
Faizah Fulyani
MMMaria Majsnerowska
Maria Majsnerowska
AVAndreja Vujičić-Žagar
Andreja Vujičić-Žagar
DSDirk Jan Slotboom
Dirk Jan Slotboom

1 January 2012 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
LPLisheng Peng
Lisheng Peng
RBRonnie P.-A Berntsson
Ronnie P.-A Berntsson
WTWilliam H. Tepp
William H. Tepp
RPRose M. Pitkin
Rose M. Pitkin
EJEric A. Johnson
Eric A. Johnson
MDMin Dong
Min Dong
Botulinum neurotoxins are classified into seven types (BoNT/A-G), but multiple subtype and mosaic toxins exist. These subtype/mosaic toxins share high sequence identity and presumably the same receptors/substrates with their parental toxins. Here we report that a mosaic toxin, BoNT/D-C, uses different receptors from its parental toxin BoNT/C. BoNT/D-C, but not BoNT/C, binds directly to the luminal domains of synaptic vesicle proteins synaptotagmin (Syt) I and II, and requires expression of Syt I/II to enter neurons. The Syt II luminal fragment containing the toxin binding site can block BoNT/D-C entry into neurons and reduce its toxicity in vivo in mice. We also found that gangliosides increase binding of BoNT/D-C to Syt I/II and enhance the ability of the Syt II luminal fragment to block BoNT/D-C entry into neurons. These data establish Syt I/II, in conjunction with gangliosides, as the receptors for BoNT/D-C, and indicate that BoNT/D-C is functionally distinct from BoNT/C. We further found that BoNT/D-C recognizes the same binding site on Syt I/II where BoNT/B and G also bind, but utilizes a receptor binding interface distinct from BoNT/B and G. Finally, we also report that human and chimpanzee Syt II cannot bind and function as the receptor for BoNT/B, D-C, and G due to a single residue change from rodent Syt II within the toxin binding site, potentially reducing the potency of these BoNTs in humans and chimpanzees.

19 March 2009 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
RBRonnie P‐A Berntsson
Ronnie P‐A Berntsson
MDMark K Doeven
Mark K Doeven
FFFabrizia Fusetti
Fabrizia Fusetti
RDRia H Duurkens
Ria H Duurkens
DSDurba Sengupta
Durba Sengupta
DSDirk Jan Slotboom
Dirk Jan Slotboom
Oligopeptide‐binding protein A (OppA) from Lactococcus lactis binds peptides of an exceptionally wide range of lengths (4–35 residues), with no apparent sequence preference. Here, we present the crystal structures of OppA in the open‐ and closed‐liganded conformations. The structures directly explain the protein's phenomenal promiscuity. A huge cavity allows binding of very long peptides, and a lack of constraints for the position of the N and C termini of the ligand is compatible with binding of peptides with varying lengths. Unexpectedly, the peptide's amino‐acid composition (but not the exact sequence) appears to have a function in selection, with a preference for proline‐rich peptides containing at least one isoleucine. These properties can be related to the physiology of the organism: L. lactis is auxotrophic for branched chain amino acids and favours proline‐rich caseins as a source of amino acids. We propose a new mechanism for peptide selection based on amino‐acid composition rather than sequence.